NASDAQ STOCKHOLM WELCOMES INFANT BACTERIAL THERAPEUTICS TO FIRST NORTH

Stockholm, March 29, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Infant Bacterial Therapeutics (“IBT”) AB’s shares (short name: IBT B) commenced today on Nasdaq First North in Stockholm. IBT belongs to the health care sector and is the 12th company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.

IBT is a pharmaceutical company developing drugs that meet the needs of premature infants. The company’s primary focus is on the clinical development of a certain drug candidate containing Lactobacillus reuteri. The drug prevents babies from getting necrotizing enterocolitis (“NEC”), a fatal disease that affects premature infants. IBT was established in 2013 and is headquartered in Stockholm, Sweden. For more information, please visit www.ibtherapeutics.com.

“We welcome all new shareholders to join us in our efforts to provide life-saving medications to the most vulnerable population in the world,” said Staffan Strömberg, CEO of IBT. “We are glad to be listed on Nasdaq First North enabling current and future shareholders to take part in our meaningful mission to satisfy the unmet medical needs of premature babies.”

“We welcome IBT to Nasdaq First North,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “IBT is yet another exciting addition to our growing health care sector, and we look forward to supporting the company with the increased investor visibility that comes with a First North listing.”

Infant Bacterial Therapeutics AB has appointed Erik Penser Bankaktiebolag as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market”

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

In This Story